Education
About Us
Working with TipRanks
Follow Us
Jasper Therapeutics (JSPR)
NASDAQ:JSPR
JSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.55 - $31.01
Previous CloseN/A
Volume4.28M
Average Volume (3M)336.03K
Market Cap
$78.27M
Enterprise Value$191.73M
Total Cash (Recent Filing)$129.40M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
May 09, 2025EPS Estimate
-1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.87
Shares Outstanding15,022,122
10 Day Avg. Volume215,894
30 Day Avg. Volume336,028
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.43
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap2.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-48.52
Forecast
1Y Price Target
$60.89Price Target Upside1068.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Jasper Therapeutics News
See All JSPR News
---
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageBriquilimab's mechanism of action is distinct and advantageous relative to the competitive landscape and the early clinical data appears to be affirming that.
Innovative Treatment ApproachesThe future landscape of CSU treatment was described in six categories, indicating a broad and innovative approach.
Positive Data TrendsThe updated results are trending positively, with the new sub-analysis supporting dose responsive efficacy for briquilimab, and safety continuing to look promising.
Bears Say
Financial ConcernsWith a cash balance of just over $70 million at the end of 2024, Jasper will clearly need to raise additional capital or secure a partnership to advance briquilimab development.
Market CompetitionThe current stock price is baking in apprehension around the balance sheet in the context of being behind CLDX from a timeline perspective.
Safety ConcernsMore follow-up will be needed to fully understand the risk of tox accumulation over time.
---
Ownership Overview
27.62% Insiders
9.56% Mutual Funds
0.02% Other Institutional Investors
54.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $4.55 and its highest was $31.01 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $78.27M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is May 09, 2025 which is in 46 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Feb 27, 2025. The company reported -$1.62 earnings per share for the quarter, missing the consensus estimate of -$1.254 by -$0.366.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate is -1.38.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 15,022,122 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$1.62 in its last earnings report, missing expectations of -$1.254. Following the earnings report the stock price went down -2.241%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
---
Jasper Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.89 (1068.71% Upside)
$60.89 (1068.71% Upside)
Blogger Sentiment
Bullish
JSPR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 239.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.44%
12-Months-Change
Fundamentals
Return on Equity
-101.73%
Trailing 12-Months
Asset Growth
-16.23%
Trailing 12-Months
Company Description
Jasper Therapeutics
Jasper Therapeutics (JSPR) is a biotechnology company focused on the development of innovative therapies for diseases of the hematopoietic system, including immunology and oncology conditions. The company is dedicated to advancing its pipeline of novel therapies aimed at improving patient outcomes by targeting the root causes of these diseases. Jasper Therapeutics' lead product candidate is designed to improve the success and safety of hematopoietic cell transplants, which are critical for treating a variety of life-threatening diseases.
---
JSPR Stock 12 Month Forecast
Average Price Target
$60.89
▲(1068.71% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering JSPR
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-34.02%
reiterated a buy rating 22 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -34.02% per trade.
---